FDA approves Amgen's treatment for most deadly form of lung cancer 

The Food and Drug Administration approved Amgen's treatment for patients with the most deadly form of lung cancer.

. That means patients can take the drug if their cancer progressed while on or after trying one other form of treatment, which is typically a type of chemotherapy. Amgen's drug is also known by its generic name tarlatamab.Small-cell lung cancer comprises 15% of cases, or 330,000, of the more than 2.2 million patients diagnosed with lung cancer worldwide each year, Amgen said. Around

Lynne Bell, a small-cell lung cancer patient from Atlanta, Georgia, is an exception. She says she was"horrified" and"in a dark place" after she was diagnosed with an advanced stage of the condition in 2021.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challengeIt may be too late for the FDA to change the sotorasib dosage, although in principle it could demand a new regimen before granting final approval, perhaps in 2028.
Source: mercnews - 🏆 88. / 68 Read more »